Sanofi (SNY) Scheduled to Post Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, April 25th. Analysts expect Sanofi to post earnings of $0.99 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Stock Up 1.1 %

SNY stock opened at $47.69 on Wednesday. The company has a fifty day moving average price of $47.58 and a 200 day moving average price of $48.45. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a market cap of $120.64 billion, a price-to-earnings ratio of 20.21, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Morgan Stanley initiated coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.